NEW YORK, August 5, 2026, 17:07 EDT
- Axon reported second-quarter revenue up 35% to $904 million, while adjusted EBITDA surpassed consensus by 9.8%.
- Shares dropped 6.5% in after-hours trading, coming after a five-day surge of 14.7%.
- Midpoint of preliminary guidance suggests second-half growth of 31.7%.
Shares of Axon Enterprise NASDAQ:AXON declined 6.5% to $569.90 in after-hours trading on Wednesday. The stock slid even after the company reported stronger-than-expected earnings and lifted its revenue outlook. Shares finished regular trading at $609.49, rising 0.4%.
Market reaction indicates investors keyed in on the pace for the back half of the year. Axon’s updated guidance points to growth between 29.8% and 33.5% during that time. The midpoint, 31.7%, comes in under the second quarter’s 35.3% rate.
Initial revenue bridge
| Metric | Low case | Midpoint | High case |
|---|---|---|---|
| 2026 revenue increase | 32.0% | 33.0% | 34.0% |
| Projected 2026 revenue | $3.669 bln | $3.697 bln | $3.725 bln |
| Projected H2 2026 revenue | $1.957 bln | $1.985 bln | $2.013 bln |
| Implied H2 annual growth | 29.8% | 31.7% | 33.5% |
| Q2 growth as reported | 35.3% | 35.3% | 35.3% |
Initial estimates are based on disclosed 2025 sales of $2.7795 billion and sales figures from the first half of 2025 and 2026.
The deceleration is slight. Despite this, the stock rose 14.7% across five sessions. The report faced elevated expectations.
The company surpassed all major projections for the quarter. Revenue came in 3.3% above consensus. Adjusted EBITDA topped estimates by 9.8%, and adjusted earnings were 2% higher than expected.
Second-quarter earnings summary
| Metric | Q2 2026 | Benchmark | Difference |
|---|---|---|---|
| Revenue | $904.4 mln | $875.9 mln consensus | +3.3% |
| Adjusted EPS | $1.88 | $1.84 consensus | +2.0% |
| Adjusted EBITDA | $242.0 mln | $220.4 mln consensus | +9.8% |
| Operating margin | 5.2% | Negative 0.2% in Q2 2025 | +540 bps |
| Free cash flow | Negative $1.0 mln | Negative $110.7 mln in Q2 2025 | +$109.7 mln |
Consensus forecasts and annual comparisons were provided right after the announcement.
Growth remained steady. Software and services increased by 36% to $398 million. Connected devices climbed 35% to $507 million. AI Era revenue surged almost 700%, and Dedrone sales exceeded $100 million.
Forward demand showed improvement. Annual recurring revenue climbed 39% to $1.639 billion. Net revenue retention was 126%. Future contracted bookings grew 41%, totaling $15.1 billion.
Comparison of Forward Demand
| Metric | Q2 2025 | Q1 2026 | Q2 2026 | Year-on-year change |
|---|---|---|---|---|
| Annual recurring revenue | $1.183 bln | $1.493 bln | $1.639 bln | +39% |
| Net revenue retention | 124% | 125% | 126% | up 2 percentage points |
| Future contracted bookings | $10.7 bln | $14.3 bln | $15.1 bln | +41% |
The bookings balance is roughly 4.1 times the midpoint of Axon’s projected 2026 sales. The company anticipates completing 20%-25% of this in the next 12 months, with the majority to be delivered throughout the subsequent 10 years.
Profit quality remains less reassuring for investors. Overall gross margin was unchanged at 60.4%. Software gross margin declined by 430 basis points, reaching 71.3%. Device margins improved by 330 basis points, largely due to tariff refunds.
The disparity between GAAP and adjusted figures continued to be significant. Net margin for Q2 stood at 3.3%, compared to an adjusted EBITDA margin of 26.8%. Stock-based compensation reached $144.3 million. Free cash flow was marginally negative.
The response was intensified by valuation. Early after-hours estimates put Axon’s value at roughly 12.4 times its projected sales. The figures also suggest around 50 times its guided adjusted EBITDA. The estimate is based on 80.6 million shares and net debt of $1.1 billion.
Axon finished Wednesday with a price-to-earnings ratio around 244 based on trailing earnings. By comparison, Motorola Solutions NYSE:MSI, its main large publicly listed rival, traded at close to 35 times. Axon’s higher growth rate and larger involvement in software help justify that valuation gap.
Prior to earnings, TheStreet Pro’s Bob Lang described the chart as “bullish.” He also pointed out soft money flow and a negative MACD. The portfolio recommended “stockpile on pullbacks” on Axon and revealed a long position. TheStreet Pro
Sell-side analysts showed mostly positive sentiment. According to FactSet, 21 out of 23 analysts rated the stock positively. Their average price target stood at $688.65, about 21% higher than the after-hours price. These targets were set before revisions following the Q2 results.
Analyst ratings prior to post-Q2 adjustments
| Recommendation | Current count | One month earlier |
|---|---|---|
| Buy | 17 | 17 |
| Overweight | 4 | 4 |
| Hold | 1 | 2 |
| Underweight | 1 | 1 |
| Sell | 0 | 0 |
| Consensus | Buy | Buy |
Analysts on average set a target of $688.65, while the median forecast stood at $700, with projections ranging from $440 to $825.
The closed cash market had already reflected expectations of a robust result. Axon surged 14.7% in the five sessions up to Wednesday. At $569.90, shares were still trading 8.5% higher than their July 30 close.
The upcoming week starts with the August 6 cash session. Market participants will track estimate revisions, software profitability, and the pace of backlog conversion. The steady 25.5% EBITDA objective keeps the spotlight on delivery.
Risks: Bookings feature extended agreements and some provisions for termination. Axon projects stock-based compensation of $590 million to $620 million in 2026. The midpoint is roughly 64% of its guided adjusted EBITDA.
Demand is still strong. The next step relies on turning that demand into cash flow and GAAP profitability.
Related articles: NASDAQ:AXON
